Fig. 2From: Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanomaOverall and Progression Free Survival comparison with patients receiving metformin for > 5 months (a-b)Back to article page